Abstract. The aim of this study was to determine whether proteasome inhibitor MG132 treatment has any effect on endothelial progenitor cells (EPCs). Total mononuclear cells (MNCs) were isolated from peripheral blood by Ficoll density gradient centrifugation. EPCs were identified as adherent cells double positive for DiLDL-up-take and lectin binding by direct fluorescent demonstrated under a laser scanning confocal microscope. After 7 days in culture, EPCs were stimulated with proteasome inhibitor MG132 in series of final concentrations of 20, 50, 100, 200 nmol/l for 12, 24, 48 h. Cell proliferation and apoptosis were determined, respectively, by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, annexin V/propidium iodide binding assay. Colony-forming capacity was performed by colony assay. EPCs adhesion and migration were assayed with adhesion assay and transwell migration assay, respectively. The expression of endothelial nitric oxide synthase (eNOS) was assayed by Western blot analysis, while nitric oxide (NO) generation was detected using the Griess method. It was found that proteasome inhibitor MG132 decreased the number of EPCs and EPC colonies, increased EPC apoptosis, decreased EPC proliferative, adhesive, migration capacity and eNOS/ NO production in a concentration-and time-dependent manner. These data indicate that proteasome inhibitor MG132 suppresses the number and function of EPCs, and these actions may involve decreased eNOS/NO production in the EPCs.
Introduction
Endothelial progenitor cells (EPCs) are the precursors of mature endothelial cells. They possess the capacity to migrate, proliferate and differentiate into endothelial lineage cells (1) . It is well known that circulating endothelial progenitor cells contribute to postnatal neovascularization and re-endothelialization (2, 3) . Moreover, many studies suggest that the number of EPCs serves as a biological marker for vascular function (4) . It is also a better predictor for future cardiovascular events (5, 6) .
There is increasing evidence that endothelial nitric oxide synthase/nitric oxide (eNOS/NO) plays significant roles in regulating the number and function of stem/progenitor cells (7) (8) (9) (10) . These studies showed that eNOS contributes to the effect of VEGF in the improvement of EPC proliferation, mobilization and serves as a significant regulator of angiogenesis (7) (8) (9) . As a significant regulator of neovascularization, NO can enhance EPC function via activating the PI3K/Akt signal pathway (10) .
The ubiquitin-proteasome system is the major pathway of nonlysosomal degradation of intracellular proteins in eukaryotic cells (11) . In addition to the degradation of damaged and unnecessary proteins, this pathway plays key roles in a variety of important intracellular events, including inflammatory processes, cell proliferation, apoptosis, and gene expression. Proteasome is the central element of this pathway. In vitro and in vivo, proteasome inhibitors possess anti-inflammatory, antiproliferative and proapoptotic features (12, 13) . It has been suggested that inhibition of the proteasome to a defined degree may offer a promising tool for treating various diseases (14) . Particularly, it was shown that lowdose proteasome inhibitiors (between 20 and 200 nmol/l) upregulated the expression and activity of eNOS, induced basal NO production and downregulated the expression of the vasoconstrictor endothelin-1 (ET-1) in primary endothelial cells (15, 16) , indicating that the partial proteasome inhibition may promote eNOS-dependent vascular protection.
It has been noted that one identical dose of proteasome inhibitor has distinct effects on different cell types (14) . Proteasome inhibition induces apoptosis in rapidly proliferating cells while protects from apoptosis in differentiated and quiescent cells (17, 18) . On the basis of the above considerations, it was of interest to see what effects proteasome inhibitor MG132 has, in the dosage between 20 and 200 nmol/l which is considered as low dosage in the endothelial cells (15, 16) , on the number and function of EPCs, and whether the eNOS/NO pathway is involved in the effects of MG132 on EPCs biology. Therefore, in this study, we investigated the effects of MG132 in the dosage between 20 and 200 nmol/l on proliferation, apoptosis, migration, adhesion, eNOS protein expression and NO production in cultured human peripheral blood EPCs.
Materials and methods
Isolation and cultivation of EPC. Human EPC were obtained from healthy adults and cultured according to previously described techniques (4, 19) . Written informed consent was obtained from all people involved in the study. The volunteers had no risk factors of CAD including hypertension, diabetes, smoking, positive family history of premature CAD and hypercholesterolemia, and were all free of wounds, ulcers, retinopathy, recent surgery, inflammatory, malignant diseases or medications that may influence EPC kinetics. Briefly, total mononuclear cells (MNC) were isolated from the peripheral venous blood of study subjects by Ficoll density gradient centrifugation. Cells were plated on culture dishes coated with human fibronectin (Chemicon) and maintained in Medium 199 (Sigma) supplemented with 20% fetal calf serum, penicillin (100 μ/ml), streptomycin (100 μg/ml) and vascular endothelial growth factor (VEGF, 50 ng/ml).
After 4 days of culture, nonadherent cells were removed by washing with phosphate-buffered saline (PBS), and adherent cells were cultured continually by the addition of new media for another 3 days. Proteasome inhibitor MG132 (carbobenzoxyl-Lleucyl-L-leucyl-L-leucinal; Sigma) was dissolved in dimethyl sulfoxide (DMSO), and attached cells were treated with series of final concentrations of 20, 50,100, 200 nmol/l for 12, 24, 48 h, respectively. These concentrations were known to inhibit partial proteasome in endothelial cells (15, 16) . The final concentration of DMSO in culture medium was 0.1% and control cells were treated with the culture medium containing an amount of dimethyl sulfoxide (DMSO) equivalent to that used in the MG132 solutions.
Cell staining. Fluorescent chemical detection of EPCs was performed on attached MNCs after 7 days in culture. Direct fluorescent staining was used to detect dual binding of FITClabelled Ulex europaeus agglutinin (UEA-1; Sigma) and 1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine (DiI)-labelled acetylated low-density lipoprotein (acLDL; Molecular Probe) at day 7. Cells were first incubated with acLDL (10 μg/ ml) at 37˚C for 4 h and then fixed with 2% paraformaldehyde for 10 min. After washing, cells were reacted with UEA-1 (10 μg/ml) for 1 h. After staining, samples were viewed using an inverted fluorescence microscope (Leica Microsystems AG, Wetzlar, Germany) and were further demonstrated by laser scanning confocal microscopy (LSCM, Leica). Cells displaying double positive fluorescence were identified as differentiating EPCs (5, 19) . Two or three independent investigators evaluated the number of EPCs per well by counting 15 randomly selected high-power fields (x200).
Colony assay. After 7 days of culture, human EPCs were gently detached with 0.25% trypsin. Cells (1x10 5 ) were seeded in methylcellulose plates (Methocult GF H4434, Cell Systems) with 100 ng/ml human recombinant VEGF in the presence or absence of MG132. Plates were studied under phase contrast microscopy, and colonies were counted after 2 days of incubation by two independent investigators (20, 21) .
EPC proliferation assay. The effect of proteasome inhibitor MG132 on EPC proliferation was determined by the MTT assay. After being cultured for 7 days, EPCs were digested with 0.25% trypsin and then were cultured in 96-well plates (10 4 cells per well) in M199 medium containing 10% fetal bovine serum in the absence or presence of different concentrations of proteasome inhibitor MG132. After incubation for 12, 24, 48 h, EPCs were incubated with 10 ml MTT (5 g/l) for another 4 h at 37˚C. Then the supernatant was removed and 150 ml dimethyl sulfoxide (DMSO) was added to each well. The culture plate was shaken for 10 min. The optical density (OD) value was read at 490 nm (19) .
EPC apoptosis assay. To identify EPC apoptosis, the apoptotic rate of EPCs was detected by the Annexin V-FITC Apoptosis detection kit (BioVision) according to the manufacturer's protocol. Briefly, after incubation with MG132 of different concentrations for 48 h, both floating and attached cells were harvested and washed twice with PBS. Isolated EPCs (5x10 6 ) were resuspended in 500 μl binding buffer. FITC-annexin V (5 μl) and propidium iodide (PI, 5μl) working solution were added and then cells were incubated at room temperature for 5 min in the dark. After the incubation period, cells were analyzed by flow cytometry (FACS Calibur, USA), the annexin V-FITC binding was analyzed by FITC signal detector (FL1) and PI staining by phycoerythrin emission signal detector (FL3). Apoptotic cells were identified as annexin V (+) and PI (-).
Cell adhesion assay. EPCs were washed with PBS and detached with 0.25% trypsin. After centrifugation and resuspension in M199 with 5% FBS, identical cell numbers were replated onto fibronectin-coated culture dishes and were incubated for 30 min at 37˚C. Adherent cells were counted in a blinded manner by independent investigators (19) .
Migration assay. EPC migration was evaluated by using a transwell migration assay. In brief, after being preincubated without or with different concentrations of MG132, isolated EPCs were detached using 0.25% trypsin, harvested by centrifugation, resuspended in 500 μl M199 and were counted; then 3x10 5 EPCs in 1500 μl culture medium were placed in the upper chamber of 8.0-mm pore size transwell. M199 (2000 μl) and human recombinant VEGF (50 ng/ml) were placed in the lower compartment. After a 24-h incubation at 37˚C, the cells that had not migrated were removed from the upper surface of the filters using cotton swabs and those that migrated to the lower surface of the filters were fixed in 4% paraformaldehyde for 10 min and stained with 2% methylrosanilinium chloride for 10 min. Migration was determined by counting the cell number at x200 magnification. Five visual fields were chosen randomly for each assay. The average number of the migrating cells in 5 fields was taken as the cell migration number of the group. Six independent experiments were examined, and the groups represent the mean of the 6 separate experiments.
Determination of NO generation. The level of nitrite/nitrate in the conditioned medium of EPCs was measured as described previously (22) . A nitrite detection kit (Beyotime Biotech Inc., Jiangsu, P.R. China) was used according to the manufacturer's instructions. Briefly, 50 μl of medium or standard NaNO 2 was mixed with 50 μl of Griess reagent in a 96-well plate. After 15 min, optical density was read in a microplate reader at 540 nm with a spectrophotometer. Each experiment was performed in triplicate. A standard curve using NaNO 2 was generated for each experiment for quantification. Results of three independent experiments were used for statistical analysis.
Western blot analysis. To assess eNOS expression, EPCs were washed 3 times with PBS and lysed with RIPA. Proteins (30 μg per lane) were denatured, loaded onto an 8.0% sodium dodecyl sulphate-polyacrylamide gel for electrophoresis (SDS-PAGE). The proteins were transferred to nitrocellulose membranes by electroblotting. Membranes were soaked in a blocking solution containing PBS with 5% non-fat dried milk and 0.05% Tween-20 for 1 h at room temperature. The membranes were then incubated with antieNOS monoclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a dilution of 1:400 at 4˚C overnight. The membrane was then incubated with peroxidase labeled with secondary antibody (Santa Cruz Biotechnology) at a dilution of 1:1000 for 2 h at room temperature. Positive protein bands were visualized with an ECL kit (Amersham, USA). Western blot analysis with a mouse polyclonal antibody raised against glyceraldehyde-3-phosphate Dehydrogease (GAPDH) (Santa Cruz Biotechnology) was used as a protein loading control. The bands corresponding to eNOS were detected using the appropriate chemiluminescence reagent (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Statistical analysis. All statistical analyses were performed with SPSS15.0. Data were expressed as mean ± SD from at least three independent experiments. One-way ANOVA and independent samples t-test were used to analyze the differences of variables. Probability values were considered significant at P<0.05.
Results

Identification of EPCs.
Total MNCs isolated and cultured for 7 days resulted in a spindle-shaped, EC-like morphology (Fig. 1) . To identify whether EPCs were present in cultured peripheral blood mononuclear cells, double fluorescence labeling for DiI-acLDL and UEA-1 was performed in the adherent cells at day 7. It was observed under confocal microscope that the most cultured adherent cells were positive for both DiI-acLDL and UEA-1 (Fig. 2) . The double positive cells were recognized as differentiating EPCs. Our group and other investigators have previously demonstrated that EPCs isolated in this fashion also exhibit many other endothelial characteristics, including expression of CD31, vWF and vascular endothelial growth factor receptor 2 (VEGFR-2) (20,21).
Effect of MG132 on EPC numbers. Incubation of isolated human EPCs with MG132 for 48 h decreased the number of EPCs in a concentration-dependent manner, which became apparent at 50 nmol/l, with a peak at 200 nmol/l (Table I) . In time-course experiments performed with an MG132 concentration of 200 nmol/l, decrease of EPC number became apparent at 12 h and reached the maximum at 48 h (Table II) . The low concentration group (20 nmol/l) showed no significant difference compared to the control group.
Effect of MG132 on proliferative capacity and clonal expansion in EPCs.
Incubation of isolated human EPCs with MG132 decreased EPC proliferative capacity in a concentration- (Table I ) and time-dependent (Table II) manner. The number of colonies was significantly lower in EPCs that had been pretreated with MG132, also in a concentrationdependent manner (Table I) . The low concentration group (20 nmol/l) showed no significant difference compared to the control group. Effect of MG132 on the migratory capacity of EPCs. The effect of MG132 on EPC migration was analyzed in a transwell migration assay. MG132 profoundly impaired cell migration, in a concentration- (Table I ) and time-dependent (Table II) manner. Table I ) and time-dependent (Table II) manner.
Effect of MG132 on apoptosis in EPCs.
Effect of MG132 on EPC adhesiveness. Incubation of isolated human EPCs with MG132 decreased EPCs adhesive capacity in a concentration-(
Effect of MG132 on NO generation in EPCs.
As demonstrated in Fig. 4 , treatment of EPCs with MG132 in a series of final concentration (0, 20, 50, 100, 200 nmol/l) for 48 h induced a decrease of NO generation in a concentration-dependent manner, which may influence the function of EPCs (10).
Effects of MG132 on eNOS protein expression in EPCs.
Western blotting was performed to determine whether MG132 affected eNOS protein expression of EPCs. Western blot analysis showed that the expression of eNOS (the relative light density values of control group and different concentration of MG132) had decreased significantly in the cells treated with MG132 in a concentration-dependent manner (Fig. 5) , suggesting that the inhibitory effect of MG132 may be mediated through decreasing eNOS protein expression. 
Discussion
The ubiquitin-proteasome system is the major proteolytic system for non-lysosomal degradation of cellular proteins involved in numerous cellular processes (11) . Due to the considerable diversity of its degradated substrates, proteasome inhibition may become a valuable and promising strategy in treating various human diseases. At the same time, a growing number of experimental studies demonstrate that it is centrally involved in the physiological and pathophysiological processes of cardiovascular diseases such as atherosclerosis Table I . Effect of MG132 on EPC number, proliferation, migration, and adhesion capacity in a dose-course experiment (mean ± SD; n=6).
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Number Proliferation Adhesion Migration Colony formation nmol/l (EPC x200) (A490 nm) (adherent cells x200) (migratory cells x200) ( Table II . Effect of 200 nmol/l MG132 on EPC number, proliferation, migration, and adhesion capacity in a timecourse experiment (mean ± SD; n=6). - (23), heart failure (24), ischemia-reperfusion injuries (25), post-intervention restenosis (26) and cardiac hypertrophy (27) . The peptide aldehyde MG132, primarily inhibiting the chymotrypsin-like function of the 20S proteasome, is comparably selective and is widely used in vitro experiments (28) . Recent animal studies and clinical trials documented that the divergent effects of proteasome inhibitors depend on the cell type and on the dosage (14) . Meiners et al demonstrated that local administration of high doses MG 132 for 5 min markedly reduced neointima formation in balloon injured carotid arteries, indicating that inhibition of proteasome activity is a new method in treatment of restenosis (26) . Furthermore, they showed that low-dose proteasome inhibition did not affect cell viability, while upregulated expression of endothelial NO synthase (eNOS) and basal NO production in primary endothelial cells (15) . In contrast, high doses induced endothelial cells to apoptosis, diminished expression of eNOS and NO production (16) .
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A biphasic dose effect of proteasome inhibitors was also observed by Veschini and his colleagues (29) . They showed that bortezomib, another proteasome inhibitor which was approved by the FDA in 2003 for the therapy of relapsed and refractory multiple myeloma (30) , exerted a double-edged effect on human umbilical vein cells (HUVECs): at low doses it allowed cell proliferation and angiogenesis, whereas at high doses, still achievable in vivo, it induced growth arrest and angiogenesis blockade. In line with the above observations, the beneficial effect of proteasome inhibitors in endothelial function has been shown by many other experiments, accompanied by enhanced expression of eNOS (15, 16, (31) (32) (33) . Thus, it seems that partial proteasome inhibition appears to offer beneficial effects on endothelial function.
Since EPCs are the precursors of mature endothelial cells and play important roles in endothelium maintenance, it is of interest to see what effects proteasome inhibitor has on the number and function of EPCs. In the present study, we treated EPCs with proteasome inhibitor MG132 in a series of final concentrations of 20, 50, 100, 200 nmol/l. These concentrations are known to inhibit partial proteasome in endothelial cells, chymotrypsin-like activity of proteasome was reduced while its caspase-and trypsin-like activities were retained (15, 16) . Our data showed that proteasome inhibitor MG132 in these dosages 1) decreased the number of EPC; 2) decreased the proliferative, migratory, adhesive, and in vitro colony forming capacity of EPC; 3) resulted in significant EPC apoptosis; and 4) decreased EPC production of eNOS/NO in a concentration-and time-dependent manner. Therefore, these results revealed that proteasome inhibitor MG132 suppresses number and function of endothelial progenitor cells and the eNOS/NO pathway may be involved in the effects of MG132 on EPC biology. Whether chymotrypsin-, caspase-and trypsinlike activities of proteasome in EPCs would change or not need further investigation. Based on the present results that MG132 exhibited inhibited effects on number and functions of EPCs, the three proteolytic activities would probably be suppressed in MG132-treated EPCs. Given the well established role of EPCs participating in neovascularization and reendothelialization, these findings demonstrate that MG132 of the dosage used in our studies can affect the EPC number and functions, which may lead to endothelial dysfunction and promote the progression of CAD.
To the best of our knowledge, the present study is the first to provide evidence of a role of the proteasome in the regulation of EPC biology. The mechanisms by which MG132 reduces the EPC number and activity remain to be determined. There are several possible explanations, one might be the increased apoptosis of endothelial progenitor cells. CD34-positive EPCs were shown to be very sensitive to apoptosis induction. Several apoptotic accelerators such as p53 and c-myc, antiapoptotic mediators such as bcl-2 and inhibitors of apoptosis are substrates of the proteasome (34) (35) (36) . Moreover, MG132 is known to induce apoptotic cell death, especially in prolifelating cells (17, 18) . Similar to rapidly proliferating tumor cells (37) , EPCs may be more hypersensitive to the proteasome inhibitors than endothelial cells. In this study, we also found that treatment of EPCs with MG132 resulted in significant apoptosis by annexin V/ propidium iodide binding assay.
Secondly, MG132 may interfere with the signaling pathways regulating EPC biology. Many studies have demonstrated that endothelial nitric oxide synthase/nitric oxide (eNOS/NO) plays a significant role in regulating the number and function of stem/progenitor cells (7) (8) (9) (10) . Our data showed MG132 down-regulated eNOS protein expression, leading to a significant decrease in NO generation, which may promote EPC apoptosis and poor function.
Govers et al (38) reported that intracellular NO productions from bovine aortic endothelial cells were reduced by 20 μM MG132 and lactacystin treatment, which is a huge difference (100-fold) in comparison to highest concentration of 0.2 μM used in our study. Interestingly, they observed that neither MG132 nor lactacystin affected eNOS expression in bovine aortic endothelial cells even at this high concentration.
While in another study, Wei et al (39) used MG132 in an increased concentration of 10 μM to treat bovine aortic endothelial cells and found a decreased eNOS serine 1179 phosphorylation in bovine aortic endothelial cells timedependently, whereas the levels of total eNOS were not significantly affected. The disagreement on eNOS protein expression between these studies and our studies may result from the following factors: different cell types, different dosages, and the interactions between them. The interesting issue here is why the low-dose proteasome inhibitor MG132 relating to endothelial cells downregulate the eNOS protein expression in EPCs. One possible explanation would be that the dosages used in our studies exerted cytotoxicity on EPCs. Similarly to endothelial cells, high doses of MG132 induced endothelial cells to apoptosis, diminished expression of eNOS and NO production (16) . Probably the dosages used in our studies may not be low and nontoxic doses to EPCs.
Moreover, the ubiquitin-proteasome pathway plays an important role in the biology of mammalian stem and progenitor cells (40) . Several studies documented that the ubiquitin-proteasome pathway was essentially involved in the regulation of survival, proliferation, differentiation, and lineage commitment of human CD34-positive hematopoietic progenitor cells (41, 42) . It has previously been shown that proteasome inhibitors exert antiangiogenic activity in in vitro and in vivo models of angiogenesis, by reducing the expression of VEGF receptor-1, VEGF secretion by endothelial cells in a dose-dependent manner (43, 44) . VEGF is one of the major angiogenic growth factors, which may induce migration, proliferation and tube formation in EPCs (45, 46) . Since sufficient amounts of exogenous VEGF were present in our medium during EPCs culture, the above mechanism may not be responsible for our findings. Though unlikely, we cannot exclude the possibility that the proteasome inhibitors may decrease VEGF activity via other mechanism, since the proteasome is involved in many cellular processes.
In conclusion, our present study showed that proteasome inhibitor MG132, at concentrations known for partial proteasome inhibition in endothelial cells (15, 16) , directly suppresses number and function of endothelial progenitor cells, which appears to disturb the eNOS/NO pathway. The detrimental effects of MG132 on EPCs may affect reendothelialization after stent implantation, and may lead to endothelial dysfunction. Pioneering work in this area is warranted and should assess the optimum dosage and side effect in local drug therapy.
